Bio Innovation Conference | Brad L. Stewart
17700
page-template-default,page,page-id-17700,page-child,parent-pageid-16863,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-17.2,qode-theme-bridge,qode_header_in_grid,wpb-js-composer js-comp-ver-5.6,vc_responsive
 

Brad L. Stewart

Brad L. Stewart

Chief Executive Officer, Immunology Partners

Mr. Stewart is a fearless leader who’s invested his career In building, and turning around, life sciences companies to maximize shareholder value.  He thrives on complex strategic opportunities and has successfully executed against challenges repeatedly while commercializing companies on a global scale.

In addition to his role as Chief Executive Officer of Immunology Partners, he serves in multiple Chief Executive, Board and Board Advisory roles.  An experienced senior executive, Mr. Stewart maintains a record of success in many specialty-areas of the life sciences industry including: immunology; oncology; transplant; orphan drugs; diagnostics; development and management of joint ventures; along with extensive management consulting and corporate strategy assignments.

Previously Mr. Stewart was Chief Executive Officer of Cylex, Inc., where he executed a turnaround for an early stage, venture capital backed company (Roche, Siemens, Canaan Partners).  Despite substantial hurdles, Mr. Stewart built one of the first global companion diagnostics businesses, which was commercialized in 18 countries with over 750,000 assays run.  He established a collaborative management culture, paired with his proven track record implementing strategic initiatives to successfully navigate growth, and was able to successfully exit the business through a highly competitive process.  The Cylex sale was so successful; it was selected as a finalist for two M&A Deal of the Year awards. 

 His previous accomplishments include the establishment and leadership of a successful U.S. business for a European pharmaceutical company; growth and diversification of an orphan drug company; strategic restructuring of the North American business unit of a global pharmaceutical company; development and management of joint ventures, including a multi-million dollar global pharmaceutical venture; creating an operational improvement business within a major global diagnostics company; and extensive management consulting and corporate strategy assignments.

STAY INFORMED. Join our mailing list to receive our email newsletter.